

# **Dietary polyphenols in the aetiology of Crohn's disease and ulcerative colitis – A multicenter European Prospective Cohort study (EPIC)**

Yunxia Lu, MD, PhD<sup>1,2,3</sup>, Raul Zamora-Ros, PhD<sup>4,7</sup>, Simon Chan, MB BChir, PhD<sup>5,6</sup>,  
Amanda J Cross, PhD<sup>1</sup>, Heather Ward, PhD<sup>1</sup>, Paula Jakszyn, MPH, PhD<sup>7</sup>, Robert Luben,  
BSc<sup>8</sup>, Jorrit L. Opstelten, MD, MSc<sup>9</sup>, Bas Oldenburg, MD, PhD<sup>9</sup>, Göran Hallmans, MD,  
PhD<sup>10</sup>, Pontus Karling, PhD<sup>11</sup>, Olof Grip, MD, PhD<sup>12</sup>, Timothy Key, DPhil, PhD<sup>13</sup>, Manuela  
M Bergmann, PhD<sup>14</sup>, Heiner Boeing, PhD<sup>14</sup>, Kim Overvad, PhD<sup>15</sup>, Domenico Palli,  
MD, MPH<sup>16</sup>, Giovanna Masala, MD, MPH<sup>17</sup>, Kay-Tee Khaw, MB, BChir, FRCP<sup>8</sup>, Antoine  
Racine, MD, MSc<sup>17,18,19</sup>, Franck Carbonnel, MD, PhD<sup>17,18,19</sup>, Marie-Christine Boutron-Ruault,  
MD, PhD<sup>17,18</sup>, Vibeke Andersen, MD<sup>20</sup>, Anja Olsen, PhD, MSc<sup>21</sup>, Anne Tjønneland, PhD,  
DMSc<sup>21</sup>, Rudolf Kaaks, PhD<sup>22</sup>, Rosario Tumino, MD, MSc<sup>23</sup>, Antonia Trichopoulou, MD,  
PhD<sup>24</sup>, Augustin Scalbert, PhD<sup>4</sup>, Elio Riboli, MD, MPH<sup>1,\*</sup> & Andrew R Hart, MB ChB,  
MD<sup>5,6,\*</sup>

## **Affiliations:**

- 1 Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom
- 2 Program in Public Health, College of Health Sciences, University of California, Irvine, California, United States
- 3 Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
- 4 Biomarker Group, Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC), Lyon, France.
- 5 Norwich Medical School, Department of Medicine, University of East Anglia, Norwich, United Kingdom
- 6 Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom
- 7 Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
- 8 Strangeways Research Laboratory, Institute of Public Health, University of Cambridge, United Kingdom
- 9 University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands
- 10 Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden

- 11 Department of Public Health and Clinical Medicine, GI unit, Umeå University, Umeå, Sweden
- 12 Department of Clinical Sciences, University Hospital, Malmö, Sweden
- 13 Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
- 14 Department of Epidemiology, German Institute of Human Nutrition, Potsdam, Germany
- 15 Department of Public Health, Section for Epidemiology, Aarhus University, Denmark
- 16 Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Centre, Florence, Italy
- 17 INSERM, Centre for Research in Epidemiology and Population Health, U1018, Team 9, Institut Gustave Roussy, F-94805, Villejuif, France
- 18 Université Paris Sud, UMRS 1018, F-94805, Villejuif, France
- 19 Department of Gastroenterology, Bicêtre University Hospital, Assistance Publique des Hôpitaux de Paris, F-94270 Le Kremlin Bicêtre, France
- 20 A. Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark, B. Focused Research unit for Molecular and Clinical Research, Institute of Regional Research- Center Sønderjylland, University of Southern Denmark, Odense, Denmark, C. Laboratory Center, Hospital of Southern Jutland, Denmark
- 21 Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
- 22 Division of Clinical Epidemiology, DKFZ-German Cancer Research Centre, Heidelberg, Germany
- 23 Cancer Registry and Histopathology Unit, "Civic - M.P.Arezzo" Hospital, ASP Ragusa, Italy
- 24 WHO Collaborating Center for Food and Nutrition Policies, Athens, Greece

\*Equally contributed

**Corresponding author:**

Yunxia Lu

Address: Program in Public Health,  
College of Health Science,  
University of California, Irvine, California,  
United States,

E-mail: yunxia.lu@uci.edu

Tel: +1 949 824 1538

Fax: +1 949 824 0529

**Running head:**

Polyphenols and inflammatory bowel diseases

**Word count:** (main text: 2879); (abstract: 272)



## Abstract

**Background** Oxidative stress may be involved in the aetiology of inflammatory disease (IBD) and whether dietary polyphenols, which possess antioxidants properties, prevent its development is unknown.

**Methods** A total of 401,326 men and women age 20-80 years from 8 countries were recruited between 1991 and 1998, and at baseline completed validated food frequency questionnaires. Dietary polyphenol intake was measured using Phenol-Explorer, a database with information on the content of 502 polyphenols. Incident cases of Crohn's diseases (CD) and ulcerative colitis (UC) were identified during the follow-up period of up to December, 2010. A nested case-control study using conditional logistic regression estimated the odds ratios (ORs), and 95% confidence intervals (CI), for polyphenol intake (categories based on quartiles) and developing CD or UC.

**Results** In total 110 CD (73% women) and 244 UC (57% women) cases were identified and matched to 440 and 976 controls, respectively. Total polyphenol intake was not associated with CD ( $P$  trend=0.17) or UC ( $P$  trend=0.16). For flavones and CD, there were reduced odds for all quartiles, which was statistically significant for the third ( $OR_{3^{th} \text{ vs } 1^{st} \text{ quartile}}=0.33$ , 95% CI: 0.15, 0.69) and there was an inverse trend across quartiles ( $P=0.03$ ). Similarly, for resveratrol, there was an inverse association with CD ( $OR_{4^{th} \text{ vs } 1^{st} \text{ quartile}}=0.40$ , 95% CI: 0.20, 0.82) with an inverse trend across quartiles ( $P=0.02$ ). No significant associations between subtypes of polyphenols and UC were found. Effect modification by smoking in CD was documented with borderline statistical significance.

**Conclusion** The data supports a potential role of flavones and resveratrol in CD; future aetiological studies should investigate these dietary components and further examine the potential for residual confounding.

**Key words** Polyphenols, Crohn's diseases, ulcerative colitis, anti-oxidants.

## Introduction

The incidence of inflammatory bowel disease (IBD) namely ulcerative colitis (UC) and Crohn's disease (CD) is rising, particularly in westernized nations (1). IBD is an important clinical problem, as patients have to take medications life-long, may require surgery and can develop serious complications, such as colorectal cancer (2,3). The aetiology of IBD has yet to be elucidated, although probably involves an abnormal immunological response to gastrointestinal luminal antigens in a genetically susceptible host (2). Documented risk factors include a positive family history (3), smoking (4, 5) and dietary components including intake of n-3 and n-6 fatty acids (6-8).

There are plausible biological mechanisms for how dietary polyphenols may prevent several gastrointestinal diseases, including IBD (9). These bioactive compounds form a large group of related organic molecules in plants, and are most abundant in: fruits, some vegetables, tea, coffee, cocoa, wine, herbs and spices (10-12). Plant polyphenols are sub-classified according to the number of phenol rings in their chemical structure. The largest class is flavonoids which is further sub-divided into flavonols, flavones, isoflavones, flavanones, anthocyanidins, and flavanols. Other major polyphenol classes are the stilbenes (resveratrol), phenolic acids (including hydroxybenzoic acids and hydroxycinnamic acids), and lignans. The subclasses of polyphenols vary in different foods e.g. flavonols are widely present in berries, apples and red onions; flavanols are mainly found in tea, cocoa and chocolate; isoflavones are commonly available in soybeans; lignans are abundant in flaxseed and sesame seed; resveratrol is affluent in grapes and wine; flavones are contained mainly in thyme, rosemary and oregano.

A potential mechanism for how polyphenols may prevent IBD is through inhibiting the biological process of oxidative stress, and the associated damage to DNA, lipids and proteins.

1 The gastrointestinal mucosa is constantly exposed to luminal pro-oxidants in foods such as  
2 alcohol, cholesterol oxides and fatty acids. Polyphenol compounds ameliorate oxidative stress  
3  
4 by acting as free radical scavengers and inducing cellular antioxidant defence modulating  
5  
6 proteins and genes expression (13, 14). Furthermore, experimental evidence suggests that  
7  
8 polyphenols may attenuate intestinal inflammation by reducing the expression of pro-  
9  
10 inflammatory proteins through influencing mitogen-activated protein kinases (MAPKs) and the  
11  
12 transcription factor nuclear factor kB (NF-kB) signalling pathways (15).  
13  
14  
15  
16  
17  
18

19 The molecular mechanisms for how polyphenols may prevent IBD need to be supported by  
20  
21 population-based epidemiological studies, demonstrating that initially well people who eat  
22  
23 lower amounts of polyphenols are more susceptible to developing UC and CD than those eating  
24  
25 more of these micronutrients. To date, no such epidemiological investigations have investigated  
26  
27 the polyphenol hypothesis, including prospective studies, the most robust observational study  
28  
29 design in nutritional epidemiology. The aim of this aetiological investigation was to conduct  
30  
31 the first such prospective cohort study investigating if dietary polyphenols are inversely  
32  
33 associated with the development of IBD in participants enrolled into the European Prospective  
34  
35 Investigation into Cancer and Nutrition Study (EPIC). Demonstrating associations would  
36  
37 support encouraging higher dietary intakes of polyphenols to reduce the incidence of IBD, and  
38  
39 possibly their assessment in randomised controlled trials as treatments in patients to improve  
40  
41 clinical outcomes.  
42  
43  
44  
45  
46  
47  
48  
49  
50

## 51 **Methods**

### 52 **Study population**

53  
54 The methodology of the main EPIC study has been previously described (16); in brief, 520,000  
55  
56 men and women were recruited in 23 collaborating centres in 10 European countries during the  
57  
58  
59  
60  
61  
62  
63  
64  
65

years 1991-1998. EPIC was originally designed to investigate habitual diet and the aetiology of common cancers in the general population. The EPIC-IBD study is a sub cohort of 401,326 initially healthy men and women without CD or UC at recruitment (supplementary table 1). The age of participants at recruitment ranged between 20 to 80 years in the 12 centres from 8 European countries namely: Denmark, Germany, Greece, France, Italy, the Netherlands, Sweden and the United Kingdom. At recruitment lifestyle factors were measured including habitual diet using country-specific food frequency questionnaires (FFQs) that included information on: smoking, alcohol intake and physical activity. The FFQs listed approximately 200 different foods and up to nine frequency of intake categories. From these FFQs, dietary polyphenol intake was assessed using the Phenol-Explorer database, which contains data on the content of 502 polyphenol compounds in 452 plant-based foods (17). The effects of cooking and food processing on the polyphenol content of foods were accounted for by applying polyphenol-specific retention factors from Phenol-Explorer to the relevant foods (17). A retention factor describes the loss or gain of a micronutrient during food processing e.g. a value of 0.40 means that 40% of the compound has been retained during processing.

In addition to total polyphenol intake, the four main subclasses, namely flavonoids, lignans, stilbenes and phenolic acids, were computed from Phenol Explorer. Total polyphenol content was calculated as the sum of the contents of the individual compounds expressed in mg/100g food fresh weight. All animal foods that contain no or only traces of polyphenols were excluded from the database. Total daily energy intake was also derived from the FFQs.

### ***Follow-up and ascertainment of IBD***

After recruitment, the sub-cohort was subsequently monitored until at least May 2004, and in some centres until December 2010, to identify incident cases of both CD and UC. New cases

of IBD were detected by several methods depending on the centre, namely local and national IBD registries, self-reported follow-up questionnaires, pathology databases and hospital in-patient records. All the clinical notes of potential cases were reviewed by local physicians to confirm the diagnoses. Those participants who developed indeterminate or microscopic colitis, or who had prevalent IBD at recruitment (including IBD diagnosed less than 18 months after recruitment) were excluded. The latter helped to ensure the nutritional data were more likely to represent habitual diet before the development of symptoms and the subsequent diagnosis of IBD.

### *Statistical analysis*

The analysis was a nested case-control design within a prospective cohort study. Four controls per case were randomly selected and matched by age at recruitment ( $\pm 6$  months), gender, date of recruitment into the study ( $\pm 3$  months) and study centre. The controls were alive on the date of diagnosis of the matched case to ensure a similar follow-up time. Absolute differences in polyphenol intake between cases and controls were compared with either a student's t-test or Wilcoxon-Mann-Whitney test according to the nature of the distributions. The intakes of polyphenols were divided into quartiles across the distribution of the cohort. Conditional logistic regression calculated the odds ratios (OR) and 95% confidence intervals (95% CI) for the dietary intake of *total* polyphenols and the subtypes: flavonoids, lignans, stilbenes, phenolic acid and the development of CD and UC separately. All of the models were analysed by adjusting for total energy intake (continuous variable), dietary fat and protein. The latter adjustment did not alter the observed associations and therefore we only kept total energy in the final model. The models were adjusted by educational level (none/primary school, technical/professional school, secondary school, longer education (including university)) and smoking (never, current or former). As cigarettes contain pro-oxidants, effect modification by



smoking status (never smokers versus ever smokers) was evaluated. All analyses were performed using SAS (The SAS Statistical Package. version 9.3, SAS institute, Gary, NC).

## Results

Overall, 110 incident cases of CD (73% women; mean age at diagnosis = 55.4 years, standard deviation (SD) 11.1) and 244 incident cases of UC (57% women; mean age at diagnosis 57.5 years, SD=10.3) were identified (Table 1). Being an ever smoker was more frequent among CD and UC cases than among controls (Table 1). There were no significant statistical differences in the median intakes of either total or any of the sub-types of polyphenols between cases and controls (total polyphenols and CD = 1091.6 mg/day vs 1164.8 mg/day; for UC = 1226.1 mg/day vs 1203.0 mg/day, respectively (Table 1)).

In the multivariable analysis for total polyphenol intake and CD, and using the first quartile as the reference category, lower odds were found for all higher quartiles, which was statistically significant in the third ( $OR_{3 \text{ vs } 1 \text{ quartile}}=0.38$ , 95% CI: 0.18, 0.79), but with no trend across quartiles (P value for trend =0.17) (Table 2). In subgroups of polyphenols, for flavones lower odds were documented in all quartiles and was statistically significant in the third ( $OR=0.33$ , 95% CI: 0.15, 0.69), with an inverse trend across quartiles (P for trend=0.03). Similarly, for resveratrol all higher quartiles were associated with lower odds, which was statistically significant for the second quartile ( $OR_{2 \text{ vs } 1 \text{ quartile}}=0.47$ , 95% CI: 0.25, 0.90) and highest quartile ( $OR=0.40$ , 95% CI: 0.20, 0.82), with an inverse trend across quartiles (P=0.02). For most other polyphenol subtypes, there were inverse, but not statistically significant, associations with higher quartiles, and no trends across categories. For isoflavones, the third quartile was positively associated with the odds of CD ( $OR_{3 \text{ vs } 1 \text{ quartile}}=2.26$ , 95% CI: 1.13-4.53), but no trend across categories (P=0.11). For total polyphenol intake and UC, there were no statistically significant associations (Table 3). For subtypes of polyphenols, there were no

associations within quartiles, apart from a higher odds ratio in the third quartile of flavanols (OR<sub>3 vs 1 quartile</sub> = 1.71, 95% CI: 1.09, 2.69) and no trends across quartiles.

Further stratified analyses were conducted by smoking status since this may hypothetically modify the effects of polyphenols. For non-smokers, there were no associations with either total or subtypes of polyphenols with CD or UC (supplementary tables 2 & 3); the exceptions were an inverse association with the second quartile of lignans and CD (OR<sub>2 vs 1 quartile</sub> = 0.06, 95% CI = 0.01-0.39), and borderline statistical significant trends for UC with flavonols (p = 0.08) and isoflavones (p = 0.07). In ever smokers (former plus current smokers), there were borderline significant trends across quartiles for flavanones (P = 0.07), flavones (P = 0.07) and lignans (P = 0.06) for CD (table 4). In ever smokers, total polyphenol intake was positively associated with UC (P trend = 0.05), although only the third quartile was statistically significant (OR<sub>3 vs 1 quartile</sub> = 2.00, 95% CI: 1.04, 3.85) (table 5). There were positive associations between phenolic acids and UC (OR<sub>3 vs 1 quartile</sub> = 2.11, 95% CI: 1.06, 4.22; OR<sub>4 vs 1 quartile</sub> = 2.14, 95% CI: 1.03, 4.46; P trend = 0.05) due to the contribution of hydroxycinnamic acid (OR<sub>3 vs 1 quartile</sub> = 2.01, 95% CI: 0.99, 4.07; OR<sub>4 vs 1 quartile</sub> = 2.35, 95% CI: 1.13, 4.91; P trend = 0.04).

## Discussion

We found no associations between *total* dietary polyphenol intake and the odds of developing either CD or UC. However, certain subtypes of polyphenols, namely flavones and resveratrol, were associated with lower odds of CD. There was some evidence of effect modification in ever smokers with suggestive inverse associations for CD with flavanones, flavones and lignans, but no associations in non-smokers for both UC and CD. The plausible biological mechanisms, magnitudes of these effect sizes, biological gradients, temporal data collection and adjustment for potential confounders suggest that these inverse associations could be protective ones. Mechanistically, certain polyphenols may prevent CD through inhibiting oxidative stress (13), which in the intestinal tract may contribute to the pathogenesis and progression of IBD (18, 19).

Recent data reported a positive correlation between reactive oxygen species (ROS), reactive nitrogen species (RNS) and gastrointestinal mucosal inflammation, which was associated with increased pro-inflammatory cytokines such as interleukin 6 (IL-6), interleukin-17A (IL-17A) and interleukin -23(IL-23) (20).

The suggestion of effect modification for certain polyphenols and CD in smokers, a process which induces oxidative stress, but not in non-smokers, provides evidence for the role of this metabolic process in the aetiology of CD. Oxidative stress develops via mechanisms including bacteriologic and immunologic pathways, which may support the varying associations of polyphenols with CD and UC; for example, antibiotic treatment for CD but not UC, and the distinct immune responses of CD (TH1 cytokine profile) and UC (TH2 profile) (the TH1 cytokine profile is involved in immune response to infection but not TH2 profile) support a possible role for the gut microbiota in CD (21). Furthermore, specific polyphenols, such as stilbenes (particularly resveratrol) may alter the composition of the gut microbial ecosystem, as supported by evidence in rats (22). Moreover, patients with active CD, compared to active UC, may have higher levels of oxidative stress characterised by higher superoxide dismutase (SOD) activity leading to H<sub>2</sub>O<sub>2</sub> production increasing lipid peroxidation, and inhibiting mitochondrial function (23). CD patients have higher ONOO<sup>-</sup> (peroxynitrite) content, a by-product of iNOS (the inducible isoform of nitric oxide synthases (NOS)) that is highly expressed in activated macrophages and neutrophils of colonic mucosa (24). Finally, polyphenols possess not only antioxidant properties but also other bioactive functions including vasodilatory, antiviral, antibacterial, anti-inflammatory and anticarcinogenic effects, as well modulating signalling pathways influencing inflammation such as phospholipase A2, cyclooxygenase, lipoxygenase and the induction of NF-kB and MAPK signalling pathways (25). Most polyphenols were associated with a decreased odds of CD, although the trends were only statistically significant for flavones and resveratrol. This may suggest either firstly

different polyphenols have varying biological activities in preventing CD, or secondly there were insufficient cases to detect significant associations in other groups. Experimental work to elucidate any differential properties of specific polyphenols and how these may influence aetiology, plus further cohort follow-up to accrue more cases is required to clarify if there are associations. In UC, there was a positive association between hydroxycinnamic acid and UC among ever smokers, but not non-smokers, although we are not aware of any biological mechanisms to explain this, and we cannot discount the possibility that this is a false positive result. Hydroxycinnamic acid is mainly obtained from coffee, and the possibility of residual confounding exists, if there is another component of coffee which increases the risk of UC.

No previous epidemiological studies, as far as we are aware, have investigated polyphenols in the aetiology of either CD or UC. However, other foods that contain these micronutrients such as fibre-rich vegetables and fruits, have been studied (12, 26). A meta-analysis (of 2 cohort studies, and 5 case-control studies) reported that total dietary fibre was associated with a decreased risk of CD (pooled OR=0.44 ,95CI: 0.29-0.69), but not UC (pooled OR=0.80, 95%CI: 0.64-1.00) (27). This inverse association for CD with fibre may be due to micronutrients in plant-based foods, such as polyphenols. Another meta-analysis of 14 case-control studies documented that consumption of vegetables was inversely associated with the risk of UC, but not CD. However, in a sub-group analysis for vegetables and CD there was a significantly inverse association for studies carried out in Europe, but not in Asia (27). The inverse association with vegetables in the European population is consistent with our findings because some polyphenols e.g. lignans, are abundant in western foods. The increased odds associated with some categories of isoflavones in CD might be linked to other conditions, such as lactose intolerance often undiagnosed in IBD sufferers who avoid dairy foods but have increased intakes of soybean foods that are rich in isoflavones (28-30). To help clarify if inverse

associations do exist with polyphenols, further observational studies, ideally prospective cohort investigations are required.

This observational study has several methodological strengths and limitations. The strengths include the prospective cohort design, which minimised both selection bias and recall bias for dietary polyphenol intake; and a full and detailed assessment of dietary polyphenol intake was derived from interpreting the FFQ using the polyphenol database specifically developed for EPIC (17). FFQs do have several limitations compared to 24-hour dietary recall or food diaries, in that a set list of certain foods' portion sizes and frequencies of intake are listed, therefore not allowing for any variations in individuals' specific intakes. Dietary assessments using weighed records of intake over a set time are not pragmatic in large scale epidemiological studies. The online resource, Phenol-Explore (<http://phenol-explorer.eu/>) is the first comprehensive database on polyphenol content of foods to be used in epidemiological studies. The latest version also includes detailed data on the effects of food processing and cooking. A further methodological strength was that all the case notes of potential IBD patients were reviewed by physicians to confirm the diagnoses to reduce measurement bias. Follow-up bias should be minimal as the number of cases identified was similar to that in a large incidence study conducted in many European countries (31). However, more cases in the analyses, particularly according to smoking status, would have allowed a better estimate of the precision of effect sizes. Further follow-up of the cohort is now being planned, including in centres not in the original EPIC-IBD study. Our findings may only be applicable to a middle-aged to elderly patient group with IBD, although the peak prevalence of both UC and CD is in younger people. However, the results are generalizable in that we studied both male and female participants from 8 countries with variation in their dietary habits, and the site of disease in the gastrointestinal tract was similar to that expected. Residual confounding may exist, namely there are other variables, possibly

1 dietary or other health-conscious behaviour, associated with polyphenols which are actually the  
2 true aetiological exposures. Polyphenols are present in several foods including fruits and  
3 vegetables, and it may be other micronutrients in these food groups that actually influence risk.  
4 The EPIC-IBD study is continuing to investigate other dietary hypotheses and polyphenols will  
5 be adjusted for any new dietary variables for which associations are detected. Furthermore,  
6 participants' diet may change over time, and as we only had one dietary measure, namely that  
7 at recruitment, this could introduce measurement error, making any smaller associations  
8 difficult to detect. However, such measurement error would introduce an under-estimate of  
9 effect sizes, rather than a spurious over-estimate. Measurement error may be reduced by  
10 controlling for total energy intake. Relatively small numbers of cases, particularly according to  
11 smoking status would mean small effect sizes may not be identified and further cohort follow-  
12 up is required to detect such differences. The higher proportions of smoking in UC was  
13 unexpected and maybe because there was just one measure of smoking, namely at recruitment  
14 which was several years before diagnosis. This may be relevant if recent cessation of smoking  
15 before the development of symptoms is important in aetiology. Finally, in this investigation  
16 multiple comparisons between polyphenols and the odds of IBD were undertaken, which could  
17 result in false positive results. Although, this is possible, it is less likely as there are plausible  
18 biological mechanisms for the inverse associations, including the suggestion of effect  
19 modification in the smoking group, and for several of these micronutrients there were biological  
20 gradients for the ORs across quartiles.

21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 In conclusion, we have reported higher intakes of some polyphenols, namely flavones and  
51 resveratrol, are associated with a lower risk of CD, but no associations with polyphenol intake  
52 for UC. In CD, inverse associations were documented for some sub-groups of polyphenols in  
53 smokers, but not non-smokers, supporting a role for oxidative stress in the aetiology. Residual  
54 confounding for other dietary variables associated with polyphenols is a possibility. Further

large prospective cohort studies are warranted to measure polyphenol intake and determine if the associations are consistent. If so, increasing the dietary intake of these micronutrients may help reduce the risk of developing CD, and support their assessment as therapies in patients with established disease.

## References

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology*. 2012;142(1):46-54 e42; quiz e30.
2. Sartor RB. Microbial influences in inflammatory bowel diseases. *Gastroenterology*. 2008;134(2):577-94.
3. Childers RE, Eluri S, Vazquez C, Weise RM, Bayless TM, Hutfless S. Family history of inflammatory bowel disease among patients with ulcerative colitis: a systematic review and meta-analysis. *Journal of Crohn's & colitis*. 2014;8(11):1480-97.
4. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. *Mayo Clinic proceedings*. 2006;81(11):1462-71.
5. Jones DT, Osterman MT, Bewtra M, Lewis JD. Passive smoking and inflammatory bowel disease: a meta-analysis. *The American journal of gastroenterology*. 2008;103(9):2382-93.
6. Tjonneland A, Overvad K, Bergmann MM, Nagel G, Linseisen J, et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. *Gut*. 2009;58(12):1606-11.
7. Bassaganya-Riera J, Hontecillas R. Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. *Current opinion in clinical nutrition and metabolic care*. 2010;13(5):569-73.
8. Chan SS, Luben R, Olsen A, Tjonneland A, Kaaks R, Lindgren S, et al. Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease. *Alimentary pharmacology & therapeutics*. 2014;39(8):834-42.
9. Dryden GW, Song M, McClain C. Polyphenols and gastrointestinal diseases. *Current opinion in gastroenterology*. 2006;22(2):165-70.
10. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. *The American journal of clinical nutrition*. 2004;79(5):727-47.
11. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. *The Journal of nutrition*. 2000;130(8S Suppl):2073S-85S.
12. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. *The American journal of gastroenterology*. 2011;106(4):563-73.
13. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease--radicals or ridiculous? *Alimentary pharmacology & therapeutics*. 2002;16(12):1997-2015.

14. Hollman PC, Cassidy A, Comte B, Heinonen M, Richelle M, Richling E, et al. The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. *The Journal of nutrition*. 2011;141(5):989S-1009S.
15. Rosillo MA, Sanchez-Hidalgo M, Cardeno A, de la Lastra CA. Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn's disease. *Biochemical pharmacology*. 2011;82(7):737-45.
16. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public health nutrition*. 2002;5(6B):1113-24.
17. Zamora-Ros R, Knaze V, Rothwell JA, Hemon B, Moskal A, Overvad K, et al. Dietary polyphenol intake in Europe: the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *European journal of nutrition*. 2015.
18. Lam G, Apostolopoulos V, Zulli A, Nurgali K. NADPH oxidases and inflammatory bowel disease. *Current medicinal chemistry*. 2015;22(17):2100-9.
19. Pereira C, Gracio D, Teixeira JP, Magro F. Oxidative Stress and DNA Damage: Implications in Inflammatory Bowel Disease. *Inflammatory bowel diseases*. 2015.
20. Piechota-Polanczyk A, Fichna J. Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. *Naunyn-Schmiedeberg's archives of pharmacology*. 2014;387(7):605-20.
21. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. *Nature clinical practice Gastroenterology & hepatology*. 2006;3(7):390-407.
22. Etxeberria U, Arias N, Boque N, Macarulla MT, Portillo MP, Martinez JA, et al. Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats. *The Journal of nutritional biochemistry*. 2015;26(6):651-60.
23. Beltran B, Nos P, Dasi F, Iborra M, Bastida G, Martinez M, et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naive and treated Crohn's disease. *Inflammatory bowel diseases*. 2010;16(1):76-86.
24. Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. *Gut*. 1995;37(2):247-55.
25. Kolacek M, Muchova J, Dvorakova M, Paduchova Z, Zitnanova I, Cierna I, et al. Effect of natural polyphenols (Pycnogenol) on oxidative stress markers in children suffering from Crohn's disease--a pilot study. *Free radical research*. 2013;47(8):624-34.
26. Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. *Gastroenterology*. 2013;145(5):970-7.
27. Liu X, Wu Y, Li F, Zhang D. Dietary fiber intake reduces risk of inflammatory bowel disease: result from a meta-analysis. *Nutrition research*. 2015.
28. Nolan-Clark D, Tapsell LC, Hu R, Han DY, Ferguson LR. Effects of dairy products on crohn's disease symptoms are influenced by fat content and disease location but not lactose content or disease activity status in a New Zealand population. *Journal of the American Dietetic Association*. 2011;111(8):1165-72.
29. Zallot C, Quilliot D, Chevaux JB, Peyrin-Biroulet C, Gueant-Rodriguez RM, Freling E, et al. Dietary beliefs and behavior among inflammatory bowel disease patients. *Inflammatory bowel diseases*. 2013;19(1):66-72.
30. Brasil Lopes M, Rocha R, Castro Lyra A, Rosa Oliveira V, Gomes Coqueiro F, Silveira Almeida N, et al. Restriction of dairy products; a reality in inflammatory bowel disease patients. *Nutricion hospitalaria*. 2014;29(3):575-81.
31. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north



and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39(5):690-7.

Table 1 Characteristics of participants in a nested case-control study within the EPIC-IBD study

Category	Crohn's disease		Ulcerative colitis	
	Cases (n=110)	Controls (n=440)	Cases (n=244)	Controls (n=976)
Gender (female %)	80(72.7)	320(72.3)	140(57.4)	565(57.9)
Age at recruitment, years (mean ± SD)	50.1(10.8)	50.1(10.7)	51.7(10.5)	51.7(10.5)
Age at diagnosis years (mean ± SD)	55.4(11.1)	-	57.5(10.3)	-
Interval between recruitment & diagnosis (mean ± SD)	5.5(2.9)	-	5.8(3.3)	-
Education(%)				
Primary school	22(20.0)	107(24.3)	68(27.8)	253(26.0)
Technical/professional school	33(30.0)	96(21.8)	62(25.4)	246(25.2)
Secondary school	30(27.3)	105(23.9)	52(21.3)	201(21.0)
Longer education(including university)	25(22.7)	125(28.4)	54(22.1)	245(25.1)
Missing	0(0.0)	7(1.6)	8(3.3)	31(3.2)
Smoking status (n, %)		*		*
Never smoked	41(37.3)	209(47.5)	65(26.6)	418(42.8)
Former smoker	28(25.5)	121(27.5)	91(37.3)	281(28.8)
Current smoker	38(34.6)	107(24.3)	82(33.6)	255(26.1)
Missing	3(2.7)	3(0.7)	6(2.5)	22(2.3)
Daily median intakes (mg/day)(inter quartile range)				

Total polyphenols		1091.6(848.8, 1517.4)	1164.8(888.8,1517.4)	1226.1(911.3,1598.5)	1203.0(872.1,1595.3)
Flavonoids		474.6(276.6, 770.6)	462.8(293.4,707.8)	512.2(306.6,739.8)	475.5(311.4,762.6)
	Anthocyanidins	25.7(9.9, 53.7)	30.4(13.8, 55.5)	23.7(11.5, 49.7)	24.0(11.5,49.0)
	Flavanols	318.4(192.6, 627.6)	327.8 (192.7, 527.1)	379.3(218.1, 581.1)	338.2(203.7,585.1)
	Flavonols	28.2(15.2, 56.9)	29.9(18.0, 52.7)	30.6(17.0,59.5)	31.5(17.8, 59.1)
	Flavanones	21.8(9.0, 48.9)	24.8(11.3, 51.7)	23.9(10.0,50.4)	26.1(10.5, 59.3)
	Flavones	7.7(5.2, 14.4)	9.5 (6.0, 14.1)	9.5( 5.3,14.5)	8.9(5.1,14.5)
	Isoflavones	0.04(0.01, 0.11)	0.03(0.01, 0.08)	0.03(0.01-0.08)	0.03(0.01,0.08)
	Lignans	1.4(1.0, 2.0)	1.4(1.1, 1.9)	1.4(1.1, 2.0)	1.4(1.0,2.0)
Stilbenes		0.3(0.1, 1.3)	0.5(0.1, 2.1)	0.5(0.1-2.1)	0.4( 0.1,2.1)
	Resveratrol	0.1(0.0, 0.2)	0.1(0.0, 0.2)	0.1(0.0-0.3)	0.1(0.0,0.2)
Phenolic acids		560.9(428.4, 806.9)	573.4(396.1, 815.0)	592.4(388.1,868.8)	571.3(365.0,821.3)
	Hydroxybenzoic acid	23.7( 8.7, 79.0)	26.1(11.1, 65.9)	27.9(8.4, 82.7)	28.6(10.4,79.8)
	Hydroxycinnamic acid	522.0(328.3. 777.4)	529.3(341.1, 770.5)	546.9(340.4,818.4)	518.4(301.0,777.3)
	Hydroxyphenylacetic	0.1(0.0, 0.3)	0.1(0.0, 0.3)	0.1(0.0,0.34)	0.1(0.0,0.3)

---

\* p<0.05

Table 2. Odds ratios (OR) of developing Crohn's disease according to quartiles of polyphenol intakes

Polyphenols	Quartile of Intake				P value for trend
		Quartile 1	Quartile 2	Quartile 3	Quartile 4
<b>Total polyphenols</b>	Cases(n)	32	30	17	31
	OR (95% CI)	1.00	0.78(0.41,1.47)	0.38(0.18,0.79)*	0.70(0.33,1.49)
<b>Flavonoids</b>	Cases(n)	32	23	23	32
	OR (95% CI)	1.00	0.76(0.41,1.43)	0.72(0.37,1.38)	0.94(0.45,1.97)
Anthocyanidins	Cases(n)	36	26	20	28
	OR (95% CI)	1.00	0.80(0.43,1.48)	0.56(0.29,1.11)	0.67(0.33,1.36)
Flavanols	Cases(n)	28	32	18	32
	OR (95% CI)	1.00	1.14(0.63,2.05)	0.67(0.34,1.34)	1.11(0.51,2.42)
Flavonols	Cases(n)	31	26	22	31
	OR (95% CI)	1.00	0.80(0.42,1.51)	0.68(0.32,1.44)	1.00(0.45,2.22)
Flavanones	Cases(n)	37	24	23	26
	OR (95% CI)	1.00	0.64(0.35,1.17)	0.57(0.30,1.10)	0.60(0.32,1.13)
Flavones	Cases(n)	36	32	12	30
	OR (95% CI)	1.00	0.88(0.49,1.60)	0.33(0.15,0.69)*	0.61(0.28,1.30)
Isoflavones	Cases(n)	22	20	40	28
	OR (95% CI)	1.00	0.98(0.50,1.92)	2.26(1.13,4.53)*	1.59(0.72,3.49)
<b>Lignans</b>	Cases(n)	36	18	27	29
	OR (95% CI)	1.00	0.47(0.24,0.93)*	0.71(0.37,1.38)	0.67(0.30,1.48)
<b>Stilbenes</b>	Cases(n)	37	32	25	21
	OR (95% CI)	1.00	0.91(0.50,1.66)	0.67(0.35,1.28)	0.53(0.26,1.08)
Resveratrol	Cases(n)	40	20	29	21
	OR (95% CI)	1.00	0.47(0.25,0.90)*	0.60(0.32,1.11)	0.40(0.20,0.82)*
<b>Phenolic acids</b>	Cases(n)	24	32	28	26

	OR (95% CI)	1.00	1.21(0.65,2.27)	1.11(0.58,2.11)	0.83(0.41,1.69)	0.55
Hydroxybenzoic acid	Cases(n)	30	27	24	29	
	OR (95% CI)	1.00	0.82(0.43,1.59)	0.77(0.37,1.59)	0.85(0.37,1.95)	0.66
Hydroxycinnamic acid	Cases(n)	25	32	26	27	
	OR (95% CI)	1.00	1.23(0.67,2.28)	0.95(0.50,1.82)	0.91(0.46,1.79)	0.60
Hydroxyphenylacetic	Cases(n)	24	26	36	24	
	OR (95% CI)	1.00	0.94(0.50,1.78)	1.39(0.76,2.56)	0.77(0.37,1.60)	0.87

---

Adjusted for: educational level, smoking and total energy; \* p<0.05

Table 3. Odds ratios (OR) of developing ulcerative colitis according to quartiles of polyphenols intake

		Quartile of Intake				P value for trend
		Quartile 1	Quartile 2	Quartile 3	Quartile 4	
<b>Total Polyphenols</b>	Cases(n)	54	61	66	63	
	OR (95% CI)	1.00	1.46(0.93,2.31)	1.59(0.97,2.61)	1.52(0.88,2.63)	0.16
<b>Flavonoids</b>	Cases(n)	66	43	78	57	
	OR (95% CI)	1.00	0.77(0.49,1.22)	1.43(0.92,2.24)	1.10(0.66,1.86)	0.26
	Anthocyanidins	Cases(n)	61	53	68	
		OR (95% CI)	1.00	1.15(0.76,1.74)	1.03(0.65,1.62)	0.36
	Flavanols	Cases(n)	60	80	58	
		OR (95% CI)	1.00	0.85(0.54,1.35)	1.71(1.09,2.69)*	0.07
	Flavonols	Cases(n)	63	53	64	
		OR (95% CI)	1.00	1.10(0.71,1.71)	0.91(0.55,1.50)	0.63
	Flavanones	Cases(n)	66	66	51	
		OR (95% CI)	1.00	1.00(0.66,1.52)	1.06(0.70,1.62)	0.38
	Flavones	Cases(n)	62	67	65	
		OR (95% CI)	1.00	0.97(0.62,1.51)	1.33(0.85,2.08)	0.14
	Isoflavones	Cases(n)	68	61	54	
		OR (95% CI)	1.00	0.91(0.59,1.40)	0.84(0.52,1.37)	0.19
<b>Lignans</b>	Cases(n)	70	56	48	70	
	OR (95% CI)	1.00	0.82(0.54,1.26)	0.72(0.45,1.15)	0.99(0.58,1.70)	0.75
<b>Stilbenes</b>	Cases(n)	64	53	64	63	
	OR (95% CI)	1.00	0.96(0.62,1.49)	1.16(0.74,1.82)	1.09(0.68,1.75)	0.57
	Resveratrol	64	48	67	65	
<b>Phenolic acids</b>		1.00	0.79(0.50,1.24)	1.30(0.82,2.04)	1.26(0.75,2.11)	0.32
	Cases(n)	55	59	60	70	
	OR (95% CI)	1.00	1.17(0.74,1.85)	1.21(0.76,1.94)	1.33(0.81,2.19)	0.28

Hydroxybenzoic acid	Cases(n)	73	49	59	63	
	OR (95%CI)	1.00	0.67(0.43,1.04)	0.83(0.53,1.32)	1.00(0.59,1.58)	0.92
Hydroxycinnamic acid	Cases(n)	52	61	56	75	
	OR (95%CI)	1.00	1.31(0.82,2.07)	1.22(0.75,1.97)	1.60(0.98,2.63)	0.10
Hydroxyphenylacetic	Cases(n)	63	57	55	69	
	OR (95%CI)	1.00	1.01(0.66,1.55)	0.93(0.59,1.46)	1.14(0.72,1.82)	0.67

---

adjusted for: educational level, smoking and total energy; \* p<0.05

Table 4. Odds ratios (OR) of developing Crohn's disease according to quartiles of polyphenol intake in ever smokers

Polyphenols	Quartile of Intake					P value for trend
		Quartile 1	Quartile 2	Quartile 3	Quartile 4	
<b>Total polyphenols</b>	Cases(n)	20	19	9	18	
	OR (95% CI)	1.00	0.73(0.29,1.83)	0.28(0.10,0.84)*	0.56(0.20,1.63)	0.13
<b>Flavonoids total</b>	Cases(n)	22	14	10	20	
	OR (95% CI)	1.00	0.69(0.28,1.70)	0.50(0.18,1.38)	1.14(0.36,3.55)	0.67
Anthocyanidins	Cases(n)	24	13	13	16	
	OR (95% CI)	1.00	0.65(0.26,1.66)	0.51(0.20,1.28)	0.69(0.24,1.96)	0.30
Flavanols	Cases(n)	20	21	5	20	
	OR (95% CI)	1.00	1.35(0.57,3.20)	0.21(0.05,0.82)*	1.82(0.51,6.51)	0.66
Flavonols	Cases(n)	20	18	11	17	
	OR (95% CI)	1.00	1.14(0.46,2.83)	0.89(0.28,2.82)	1.07(0.31,3.65)	0.99
Flavanones	Cases(n)	23	13	12	18	
	OR (95% CI)	1.00	0.33(0.13,0.82) *	0.37(0.13,1.06)	0.40(0.17,0.97) *	0.07
Flavones	Cases(n)	25	19	5	17	
	OR (95% CI)	1.00	0.67(0.28,1.59)	0.15(0.04,0.54) *	0.56(0.20,1.58)	0.07
Isoflavones	Cases(n)	11	10	25	20	
	OR (95% CI)	1.00	0.96(0.32,2.87)	3.69(1.15,11.85) *	2.32(0.66,8.11)	0.12
<b>Lignans</b>	Cases(n)	23	14	14	15	



		OR (95% CI)	1.00	0.52(0.21,1.29)	0.38(0.13,1.12)	0.38(0.12,1.19)	0.06
<b>Stilbenes</b>	Cases(n)	21	18	14	13		
	OR (95% CI)	1.00	1.03(0.43,2.51)	0.66(0.25,1.73)	0.57(0.20,1.64)	0.19	
Resveratrol	Cases(n)	25	9	19	13		
	OR (95% CI)	1.00	0.42(0.16,1.13)	0.72(0.30,1.73)	0.39(0.14,1.07)	0.14	
<b>Phenolic acids</b>	Cases(n)	14	22	16	14		
	OR (95% CI)	1.00	1.14(0.45,2.89)	0.90(0.33,2.49)	0.71(0.26,1.96)	0.37	
Hydroxybenzoic acid	Cases(n)	17	19	14	16		
	OR (95% CI)	1.00	1.28(0.49,3.35)	1.32(0.47,3.74)	1.42(0.39,5.15)	0.58	
Hydroxycinnamic acid	Cases(n)	14	22	14	16		
	OR (95% CI)	1.00	1.71(0.67,4.41)	1.00(0.36,2.79)	1.10(0.40,3.01)	0.71	
Hydroxyphenylacetic	Cases(n)	14	16	20	16		
	OR (95% CI)	1.00	0.82(0.33,2.04)	1.56(0.64,3.80)	1.01(0.37,2.74)	0.56	

adjusted for educational level and total energy; \* p<0.05

Table 5. Odds ratios (OR) of developing ulcerative colitis and polyphenol intake in ever smokers

Polyphenols	Quartile of Intake				P value for trend
		Quartile 1	Quartile 2	Quartile 3	Quartile 4
<b>Total polyphenols</b>	Cases(n)	39	38	49	47
	OR (95%CI)	1.00	1.41(0.76, 2.64)	2.00(1.04,3.85)*	2.04(0.95,4.36)
<b>Flavonoids total</b>	Cases(n)	49	33	53	38
	OR (95%CI)	1.00	0.86(0.48,1.55)	1.41(0.79,2.52)	1.23(0.61,2.47)
Anthocyanidins	Cases(n)	43	44	40	46
	OR (95%CI)	1:00	1.45(0.83,2.52)	1.37(0.75,2.49)	1.50(0.81,2.78)
Flavanols	Cases(n)	47	35	52	39
	OR (95%CI)	1:00	0.89(0.51,1.56)	1.44(0.81,2.57)	1.26(0.64,2.51)
Flavonols	Cases(n)	49	48	36	40
	OR (95%CI)	1:00	0.97(0.55,1.74)	0.70(0.36,1.36)	1.06(0.54,2.09)
Flavanones	Cases(n)	42	46	47	38
	OR (95%CI)	1:00	1.71(0.97,3.03)	1.33(0.76,2.32)	1.05(0.58,1.91)
Flavones	Cases(n)	47	31	51	44
	OR (95%CI)	1:00	0.93(0.52,1.65)	1.55(0.88,2.74)	1.34(0.66,2.72)
Isoflavones	Cases(n)	47	45	42	39
	OR (95%CI)	1:00	1.04(0.59,1.80)	0.80(0.43,1.50)	0.55(0.26,1.16)
<b>Lignans</b>	Cases(n)	50	41	36	46
	OR (95%CI)	1:00	0.96(0.56,1.65)	0.78(0.43,1.42)	1.00(0.48,2.08)
<b>Stilbenes</b>	Cases(n)	44	41	45	43
	OR (95%CI)	1:00	1.08(0.60,1.94)	1.21(0.65,2.25)	0.98(0.52,1.87)
Resveratrol	Cases(n)	44	38	46	45
	OR (95%CI)	1:00	0.92(0.51,1.65)	1.37(0.76,2.47)	1.02(0.54,1.90)

<b>Phenolic acids</b>	Cases(n)	31	43	46	53	
	OR (95%CI)	1:00	1.70(0.88,3.29)	2.11(1.06,4.22)*	2.14(1.03,4.46)*	<b>0.05</b>
Hydroxybenzoic acid	Cases(n)	56	36	41	40	
	OR (95%CI)	1:00	0.71(0.41,1.23)	0.78(0.43,1.40)	0.85(0.45,1.61)	0.60
Hydroxycinnamic acid	Cases(n)	28	46	44	55	
	OR (95%CI)	1:00	1.85(0.96,3.56)	2.01(0.99,4.07)	2.35(1.13,4.91) *	0.04*
Hydroxyphenylacetic	Cases(n)	48	41	36	48	
	OR (95%CI)	1:00	0.93(0.53,1.63)	0.61(0.33,1.15)	1.01(0.54,1.88)	0.78

adjusted for educational level and total energy; \* p<0.05

Supplemental Table 1. Participating Centers and Characteristics of the Cohorts

Centre and country	Size of Cohort	Nature of cohort	No. Cases of Incident CD	No. Cases of Incident UC
<b>United Kingdom</b>				
Norfolk	25,639	Population-based cohort of men and women aged 45–74 yr. Recruited between 1993 and 1997. Cases identified up to June 2004 from follow up questionnaires, in-patient admission data and histopathology records.	11	27
Oxford	50,070	Members of United Kingdom vegetarian societies and readers of health food magazines (78% women), aged 20–80 yr recruited between 1994 and 1999. Cases identified up to May 2004 by follow-up questionnaires.	4	15
<b>Germany</b>				
Heidelberg	25,540	Population-based cohort of men aged 45–65 yr and women aged 35–65 yr. Recruited between 1994 and 1998. Cases identified up to June 2007 from follow-up questionnaires.	9	4
Potsdam	27,548	Population-based cohort, men and women, aged 35–64 yr. Recruited between 1994 and 1998. Cases identified up to April 2007 from follow-up Questionnaires.	4	13
<b>Italy</b>				
Florence	13,583	Population-based cohort, men and women, aged 34–64 yr. Recruitment Between 1993 and 1998. Cases identified from regional database of IBD up to May 2004.	2	8
Ragusa	6403	Population-based cohort, men and women, aged 34–65 yr recruited between 1993 and 1997. Case identified up to end of 2010 from follow-up questionnaires, in-patient admission data and histopathology records.	3	19
<b>Sweden</b>				
Umeå	25,732	Population-based cohort, men and women, aged 30–60 yr. Recruited between 1992 and 1996. Cases identified up to February 2007 from regional database of IBD.	10	15
Malmö	28,098	Population-based cohort, men and women, aged 45–69 yr. Recruited between 1991 and 1996. Cases identified up to October 2003 from regional database of IBD.	11	21
<b>Denmark</b>				
Aarhus and Copenhagen	57,053	Population-based cohort of men and women aged 50–64 yr. Recruited between 1993 and 1997. Cases identified up to July 2007 from national database of IBD	11	40
<b>France</b>				
Regions throughout the country	72,996	Women aged 40–65 yr recruited between 1990 and 1993 who are members of a health insurance scheme for school teachers and co-workers. Cases identified up to April 2008 by follow-up questionnaires.	21	28
<b>The Netherlands</b>				
Amsterdam, Doetinchem, Maastricht, and Utrecht	40,092	Men and women, aged 20–70 yr recruited between 1993 and 1997 from the general population of 3 cities (Amsterdam, Doetinchem, and Maastricht) and also the breast cancer screening program in Utrecht. Cases identified up to December 2009 by regional IBD databases	17	41
Greece	28,572	Population-based cohort of men and women aged 29–76 yr recruited between 1994 and 1999 from 11 regions throughout Greece. Cases identified up to September 2011 from follow-up questionnaires and histopathology records	7	13
Total	401,326		110	244

Supplemental Table 2. Odds ratios (OR) of Crohn's disease according to quartiles of polyphenol intake in non-smokers

Polyphenols	Quartile of Intake				P value for trend
		Quartile 1	Quartile 2	Quartile 3	Quartile 4
<b>Total polyphenols</b>	Cases(n)	11	11	7	12
	OR (95%CI)	1:00	0.58(0.15,2.30)	0.21(0.04,1.12)	0.38(0.08,1.95)
<b>Flavonoids total</b>	Cases(n)	8	9	12	12
	OR (95%CI)	1:00	1.11(0.29,4.30)	0.90(0.20,4.03)	1.20(0.21,6.72)
Anthocyanidins	Cases(n)	10	12	7	12
	OR (95%CI)	1:00	1.18(0.33,4.28)	0.93(0.24,3.65)	1.09(0.24,4.91)
Flavanols	Cases(n)	7	9	13	12
	OR (95%CI)	1:00	1.04(0.25,4.36)	1.08(0.24,4.88)	1.19(0.20,7.11)
Flavonols	Cases(n)	10	7	10	14
	OR (95%CI)	1:00	0.86(0.21,3.46)	1.07(0.27,4.22)	1.72(0.39,7.61)
Flavanones	Cases(n)	14	11	10	6
	OR (95%CI)	1:00	2.07(0.53,8.10)	1.15(0.32,4.08)	0.97(0.30,3.12)
Flavones	Cases(n)	11	13	7	10
	OR (95%CI)	1:00	0.97(0.30,3.10)	0.59(0.17,2.10)	0.72(0.19,2.71)
Isoflavones	Cases(n)	10	10	13	8
	OR (95%CI)	1:00	1.19(0.37,3.86)	1.83(0.45,7.43)	1.55(0.35,6.79)
<b>Lignans</b>	Cases(n)	13	4	13	11
	OR (95%CI)	1:00	0.06(0.01,0.39)	0.41(0.13,1.35)	0.25(0.06,1.10)
<b>Stilbenes</b>	Cases(n)	10	12	11	8
	OR (95%CI)	1:00	1.77(0.50,6.29)	1.27(0.34,4.71)	0.58(0.12,2.78)
Resveratrol	Cases(n)	13	10	10	8
	OR (95%CI)	1:00	0.60(0.16,2.19)	0.46(0.11,1.98)	0.32(0.07,1.43)

<b>Phenolic acids</b>	Cases(n)	10	9	12	10	
	OR (95%CI)	1:00	1.07(0.30,3.80)	0.85(0.27,2.71)	0.87(0.23,3.30)	0.76
Hydroxybenzoic acid	Cases(n)	12	6	10	13	
	OR (95%CI)	1:00	<b>0.15(0.02,0.96)*</b>	0.22(0.03,1.46)	0.38(0.05,2.81)	0.91
Hydroxycinnamic acid	Cases(n)	11	9	12	9	
	OR (95%CI)	1:00	0.76(0.22,2.60)	0.96(0.35,2.65)	0.57(0.15,2.20)	0.56
Hydroxyphenylacetic	Cases(n)	10	9	15	7	
	OR (95%CI)	1:00	0.92(0.25,3.47)	1.55(0.49,4.95)	0.49(0.09,2.54)	0.77

---

adjusted for: educational level and total energy; \* p<0.05

Supplemental Table 3. Odds ratios (OR) of ulcerative colitis according to quartiles of polyphenol intake in non-smokers

Polyphenols	Quartile of Intake				P value for trend
		Quartile 1	Quartile 2	Quartile 3	Quartile 4
<b>Total polyphenols</b>	Cases(n)	14	22	15	14
	OR (95%CI)	1:00	1.79(0.68,4.71)	0.95(0.29,3.07)	0.97(0.30,3.09)
<b>Flavonoids total</b>	Cases(n)	15	10	24	16
	OR (95%CI)	1:00	0.62(0.21,1.86)	1.69(0.60,4.76)	0.91(0.29,2.82)
Anthocyanidins	Cases(n)	13	18	13	21
	OR (95%CI)	1:00	0.99(0.37,2.65)	0.72(0.24,2.19)	0.97(0.28,3.31)
Flavanols	Cases(n)	11	10	28	16
	OR (95%CI)	1:00	0.97(0.30,3.08)	2.80(0.93,8.47)	1.45(0.40,5.29)
Flavonols	Cases(n)	12	15	16	22
	OR (95%CI)	1:00	1.11(0.36,3.44)	1.68(0.55,5.12)	2.42(0.74,7.98)
Flavanones	Cases(n)	22	14	18	11
	OR (95%CI)	1:00	0.77(0.30,1.94)	0.85(0.33,2.16)	0.61(0.23,1.65)
Flavones	Cases(n)	13	18	14	20
	OR (95%CI)	1:00	1.77(0.55,5.75)	0.82(0.25,2.71)	1.99(0.56,7.13)
Isoflavones	Cases(n)	18	16	17	14
	OR (95%CI)	1:00	0.60(0.21,1.76)	0.48(0.12,1.91)	0.17(0.03,1.05)
<b>Lignans</b>	Cases(n)	18	13	11	23
	OR (95%CI)	1:00	0.44(0.17,1.13)	0.23(0.07,0.71)	0.71(0.26,1.96)
<b>Stilbenes</b>	Cases(n)	17	10	18	20
	OR (95%CI)	1:00	0.50(0.20,1.30)	0.97(0.36,2.64)	0.82(0.28,2.40)
Resveratrol	Cases(n)	16	9	20	20
	OR (95%CI)	1:00	0.59(0.20,1.75)	1.08(0.41,2.88)	0.90(0.31,2.59)
<b>Phenolic acids</b>	Cases(n)	23	14	14	14

	OR (95%CI)	1:00	0.55(0.22,1.34)	0.70(0.27,1.80)	0.57(0.21,1.56)	0.35
Hydroxybenzoic acid	Cases(n)	15	11	18	21	
	OR (95%CI)	1:00	0.59(0.20,1.79)	1.26(0.40,3.96)	1.87(0.65,5.40)	0.16
Hydroxycinnamic acid	Cases(n)	22	14	12	17	
	OR (95%CI)	1:00	0.63(0.24,1.63)	0.65(0.25,1.69)	0.82(0.33,2.06)	0.65
Hydroxyphenylacetic	Cases(n)	13	14	19	19	
	OR (95%CI)	1:00	0.79(0.29,2.13)	1.30(0.50,3.37)	0.97(0.37,2.55)	0.78

---

adjusted for: educational level and total energy; \* p<0.05